Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Regeneron Pharmaceuticals has received an average recommendation of "Moderate Buy" from 28 ratings firms, with the average 12-month target price set at approximately $817.67.
• Recent institutional investment activity includes Vanguard increasing its stake by 1.3% and Dodge & Cox boosting their stake by a substantial 64.6%.
• The company reported earnings of $12.89 per share for the last quarter, significantly surpassing analyst expectations of $8.43 and reflecting a revenue growth of 3.6% year-over-year.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have issued a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $817.6667.

A number of equities research analysts recently weighed in on REGN shares. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Citigroup reiterated a "buy" rating and set a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Marietta Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after acquiring an additional 2,501 shares during the last quarter. Sepio Capital LP grew its holdings in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after purchasing an additional 842 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after purchasing an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock worth $16,255,000 after purchasing an additional 955 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock worth $94,779,000 after purchasing an additional 12,793 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $6.72 during midday trading on Friday, reaching $591.99. The company had a trading volume of 2,177,965 shares, compared to its average volume of 914,839. The company's 50 day moving average price is $567.77 and its 200 day moving average price is $575.13. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a market cap of $62.74 billion, a P/E ratio of 14.92, a P/E/G ratio of 1.98 and a beta of 0.35. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $1,154.56.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the prior year, the firm earned $11.56 earnings per share. The company's revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.